INMB News and Press, INmune Bio Inc. From 05/14/23

2023-05-14 12:00:49 ET Leqembi, the new Alzheimer's therapy developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), could add $2B - $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study. Early th...

INmune Bio (NASDAQ: INMB) , a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease, announced that its Investigational New Drug (“IND”) application for INKmune(TM), a novel natural killer (“NK”...

Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate Cancer Webinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and D...

2023-05-03 22:00:20 ET INmune Bio, Inc. (INMB) Q1 2023 Earnings Conference Call May 03, 2023 04:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Part...

2023-05-03 16:48:33 ET INmune Bio press release ( NASDAQ: INMB ): Q1 GAAP EPS of -$0.36. As of March 31, 2023, the Company had cash and cash equivalents of approximately $51.0 million. For further details see: INmune Bio GAAP EPS of -$0.36

BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial ...

2023-05-02 17:35:56 ET Major earnings expected after the bell on Wednesday include: QUALCOMM Incorporated ( QCOM ) Realty Income corporation ( O ) MercadoLibre ( MELI ) ETSY ( ETSY ) Fastly ( FSLY ) For further details see: Notable earning...

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patien...

2023-04-24 05:00:05 ET Summary Final results from the phase 2 study using XPro for the treatment of patients with mild AD and mild cognitive impairment are expected in the 2nd half of 2024. It is estimated that the global market opportunity for Alzheimer's Disease could reach $17....

TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™ Boca Raton, Florida, April 19, 2023 (GLOBE NEWSWIRE) -- INmune Bio, In...